p53 amino-terminus region (1-125) stabilizes and restores heat denatured p53 wild phenotype

PLoS ONE

Volumn 4, Issue 10, 2009, Pages

  Sharman, Anuj Kumar ^a   Ali, Amjad ^a   Gogna, Rajan ^a   Singh, Amir Kumar ^a   Pati, Uttam ^a  

^a JAWAHARLAL NEHRU UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN BAX; PROTEIN NOXA; PROTEIN P21; PROTEIN P53; PUMA PROTEIN; SUMO PROTEIN; PROLINE;

5' UNTRANSLATED REGION; AMINO TERMINAL SEQUENCE; ARTICLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOPLASM; DOWNSTREAM PROCESSING; ENZYME LINKED IMMUNOSORBENT ASSAY; HEAT STRESS; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; MUTANT; PHENOTYPE; PROTEIN AGGREGATION; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN DENATURATION; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; PROTEIN TRANSPORT; RESIDUE ANALYSIS; THERMOSTABILITY; TRANSCRIPTION INITIATION; WILD TYPE; APOPTOSIS; CELL NUCLEUS; CHEMISTRY; CIRCULAR DICHROISM; DOSE RESPONSE; GENE EXPRESSION REGULATION; HEAT; METABOLISM; PHYSIOLOGY; PROTEIN TERTIARY STRUCTURE; TUMOR SUPPRESSOR GENE;

APOPTOSIS; CELL NUCLEUS; CIRCULAR DICHROISM; CYTOPLASM; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION; GENES, P53; HOT TEMPERATURE; HUMANS; PHENOTYPE; PROLINE; PROTEIN CONFORMATION; PROTEIN DENATURATION; PROTEIN STRUCTURE, TERTIARY; TUMOR SUPPRESSOR PROTEIN P53;

EID: 70449570510     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0007159     Document Type: Article

References (51)

1. Joerger AC, Fersht AR (2008) Structural biology of the tumor suppressor p53. Annu Rev Biochem 77: 557-582.
2. Hansen S, Lane DP, Midgley CA (1998) The N terminus of the murine p53 tumour suppressor is an independent regulatory domain affecting activation and thermostability. J Mol Biol 275: 575-588.
3. Dawson R, Muller L, Dehner A, Klein C, Kessler H, et al. (2003) The N-terminal domain of p53 is natively unfolded. J Mol Biol 332: 1131-1141.
4. Fields S, Jang SK (1990) Presence of a potent transcription activating sequence in the p53 protein. Science 249: 1046-1049.
5. Matas D, Sigal A, Stambolsky P, Milyavsky M, Weisz L, et al. (2001) Integrity of the N-terminal transcription domain of p53 is required for mutant p53 interference with drug-induced apoptosis. EMBO J 20: 4163-4172.
6. Baptiste N, Friedlander P, Chen X, Prives C (2002) The proline-rich domain of p53 is required for cooperation with anti-neoplastic agents to promote apoptosis of tumor cells. Oncogene 21: 9-21.
7. Roth J, Koch P, Contente A, Dobbelstein M (2000) Tumor-derived mutations within the DNA-binding domain of p53 that phenotypically resemble the deletion of the proline-rich domain. Oncogene 19: 1834-1842.
8. Kussie PH, Gorina S, Marechal V, Elenbaas B, Moreau J, et al. (1996) Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 274: 948-953.
9. Cain C, Miller S, Ahn J, Prives C (2000) The N terminus of p53 regulates its dissociation from DNA. J Biol Chem 275: 39944-39953.
10. Xirodimas DP, Lane DP (1999) Molecular evolution of the thermosensitive PAb1620 epitope of human p53 by DNA shuffling. J Biol Chem 274: 28042-28049.
11. Muller-Tiemann BF, Halazonetis TD, Elting JJ (1998) Identification of an additional negative regulatory region for p53 sequence-specific DNA binding. Proc Natl Acad Sci U S A 95: 6079-6084.
12. Protopopova M, Selivanova G (2003) Inhibition of p53 activity in vitro and in living cells by a synthetic peptide derived from its core domain. Cell Cycle 2: 592-595.
13. Hansen S, Hupp TR, Lane DP (1996) Allosteric regulation of the thermostability and DNA binding activity of human p53 by specific interacting proteins. CRC Cell Transformation Group. J Biol Chem 271: 3917-3924.
14. Matas D, Sigal A, Stambolsky P, Milyavsky M, Weisz L, et al. (2001) Integrity of the N-terminal transcription domain of p53 is required for mutant p53 interference with drug-induced apoptosis. EMBO J 20: 4163-4172.
15. Cregan SP, Arbour NA, Maclaurin JG, Callaghan SM, Fortin A, et al. (2004) p53 activation domain 1 is essential for PUMA upregulation and p53-mediated neuronal cell death. J Neurosci 24: 10003-10012.
16. Courtois S, Verhaegh G, North S, Luciani MG, Lassus P, et al. (2002) DeltaN-p53, a natural isoform of p53 lacking the first transactivation domain, counteracts growth suppression by wild-type p53. Oncogene 21: 6722-6728.
17. Bykov VJ, Issaeva N, Zache N, Shilov A, Hultcrantz M, et al. (2005) Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs. J Biol Chem 280: 30384-30391.
18. Okorokov AL, Sherman MB, Plisson C, Grinkevich V, Sigmundsson K, et al. (2006) The structure of p53 tumour suppressor protein reveals the basis for its functional plasticity. EMBO J 25: 5191-5200.
19. Park SM, Jung HY, Kim TD, Park JH, Yang CH, et al. (2002) Distinct roles of the N-terminal-binding domain and the C-terminal-solubilizing domain of alpha-synuclein, a molecular chaperone. J Biol Chem 277: 28512-28520.
20. Bhattacharyya J, Das KP (1999) Molecular chaperone-like properties of an unfolded protein, alpha(s)-casein. J Biol Chem 274: 15505-15509.
21. Tompa P, Csermely P (2004) The role of structural disorder in the function of RNA and protein chaperones. FASEB J 18: 1169-1175.
22. Bell S, Klein C, Muller L, Hansen S, Buchner J (2002) p53 contains large unstructured regions in its native state. J Mol Biol 322: 917-927.
23. Kim AL, Raffo AJ, Brandt-Rauf PW, Pincus MR, Monaco R, et al. (1999) Conformational and molecular basis for induction of apoptosis by a p53 C-terminal peptide in human cancer cells. J Biol Chem 274: 34924-34931.
24. Walerych D, Kudla G, Gutkowska M, Wawrzynow B, Muller L, et al. (2004) Hsp90 chaperones wild-type p53 tumor suppressor protein. J Biol Chem 279: 48836-48845.
25. Tripathi V, Ali A, Bhat R, Pati U (2007) CHIP chaperones wild type p53 tumor suppressor protein. J Biol Chem 282: 28441-28454.
26. Issaeva N, Friedler A, Bozko P, Wiman KG, Fersht AR, et al. (2003) Rescue of mutants of the tumor suppressor p53 in cancer cells by a designed peptide. Proc Natl Acad Sci U S A 100: 13303-13307.
27. Milner J, Watson JV (1990) Addition of fresh medium induces cell cycle and conformation changes in p53, a tumour suppressor protein. Oncogene 5: 1683-1690.
28. Sabapathy K, Klemm M, Jaenisch R, Wagner EF (1997) Regulation of ES cell differentiation by functional and conformational modulation of p53. EMBO J 16: 6217-6229.
29. Gaitonde SV, Riley JR, Qiao D, Martinez JD (2000) Conformational phenotype of p53 is linked to nuclear translocation. Oncogene 19: 4042-4049.
30. Zerrahn J, Deppert W, Weidemann D, Patschinsky T, Richards F, et al. (1992) Correlation between the conformational phenotype of p53 and its subcellular location. Oncogene 7: 1371-1381.
31. Ryan JJ, Clarke MF (1994) Alteration of p53 conformation and induction of apoptosis in a murine erythroleukemia cell line by dimethylsulfoxide. Leuk Res 18: 617-621.
32. Hupp TR, Meek DW, Midgley CA, Lane DP (1992) Regulation of the specific DNA binding function of p53. Cell 71: 875-886.
33. Cain C, Miller S, Ahn J, Prives C (2000) The N terminus of p53 regulates its dissociation from DNA. J Biol Chem 275: 39944-39953.
34. Friedler A, Hansson LO, Veprintsev DB, Freund SM, Rippin TM, et al. (2002) A peptide that binds and stabilizes p53 core domain: chaperone strategy for rescue of oncogenic mutants. Proc Natl Acad Sci U S A 99: 937-942.
35. Selivanova G, Iotsova V, Okan I, Fritsche M, Strom M, et al. (1997) Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain. Nat Med 3: 632-638.
36. Hegyi H, Tompa P (2008) Intrinsically disordered proteins display no preference for chaperone binding in vivo. PLoS Comput Biol 4: e1000017.
37. Zylicz M, King FW, Wawrzynow A (2001) Hsp70 interactions with the p53 tumour suppressor protein. EMBO J 20: 4634-4638.
38. Wawrzynow B, Zylicz A, Wallace M, Hupp T, Zylicz M (2007) MDM2 chaperones the p53 tumor suppressor. J Biol Chem 282: 32603-32612.
39. Dunker AK (2007) Another window into disordered protein function. Structure 15: 1026-1028.
40. Uesugi M, Verdine GL (1999) The alpha-helical FXXPhiPhi motif in p53: TAF interaction and discrimination by MDM2. Proc Natl Acad Sci U S A 96: 14801-14806.
41. Bochkareva E, Kaustov L, Ayed A, Yi GS, Lu Y, et al. (2005) Single-stranded DNA mimicry in the p53 transactivation domain interaction with replication protein A. Proc Natl Acad Sci U S A 102: 15412-15417.
42. Di Lello P, Jenkins LM, Jones TN, Nguyen BD, Hara T, et al. (2006) Structure of the Tfb1/p53 complex: Insights into the interaction between the p62/Tfb1 subunit of TFIIH and the activation domain of p53. Mol Cell 22: 731-740.
43. Seo YR, Kelley MR, Smith ML (2002) Selenomethionine regulation of p53 by a ref1-dependent redox mechanism. Proc Natl Acad Sci U S A 99: 14548-14553.
44. Bykov VJ, Selivanova G, Wiman KG (2003) Small molecules that reactivate mutant p53. Eur J Cancer 39: 1828-1834.
45. Beretta GL, Gatti L, Benedetti V, Perego P, Zunino F (2008) Small molecules targeting p53 to improve antitumor therapy. Mini Rev Med Chem 8: 856-868.
46. Toledo F, Lee CJ, Krummel KA, Rodewald LW, Liu CW, et al. (2007) Mouse mutants reveal that putative protein interaction sites in the p53 proline-rich domain are dispensable for tumor suppression. Mol Cell Biol 27: 1425-1432.
47. Sakamuro D, Sabbatini P, White E, Prendergast GC (1997) The polyproline region of p53 is required to activate apoptosis but not growth arrest. Oncogene 15: 887-898.
48. Zhu J, Zhang S, Jiang J, Chen X (2000) Definition of the p53 functional domains necessary for inducing apoptosis. J Biol Chem 275: 39927-39934.
49. Ma B, Tsai CJ, Nussinov R (2000) Binding and folding: in search of intramolecular chaperone-like building block fragments. Protein Eng 13: 617-627.
50. Matsumoto S, Tanaka E, Nemoto TK, Ono T, Takagi T, et al. (2002) Interaction between the N-terminal and middle regions is essential for the in vivo function of HSP90 molecular chaperone. J Biol Chem 277: 34959-34966.
51. Greenfield NJ (2006) Using circular dichroism spectra to estimate protein secondary structure. Nat Protoc 1: 2876-2890.